<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cyclopentenone <z:chebi fb="11" ids="26333">prostaglandins</z:chebi> are potent inhibitors of nuclear factor-kappa B (NF-kappa B), a transcription factor with a critical role in promoting <z:mp ids='MP_0001845'>inflammation</z:mp> and connected with multiple aspects of <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell survival </plain></SENT>
<SENT sid="1" pm="."><plain>In the present report, we investigated the role of NF-kappa B in the <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> activity of the cyclopentenone <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> 15-deoxy-Delta(12,14)-<z:chebi fb="0" ids="26346">PGJ</z:chebi>(2) (15d-<z:chebi fb="0" ids="26346">PGJ</z:chebi>(2)) in <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cells expressing constitutively active NF-kappa B </plain></SENT>
<SENT sid="2" pm="."><plain>15d-<z:chebi fb="0" ids="26346">PGJ</z:chebi>(2) was found to suppress constitutive NF-kappa B activity and potently induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in both types of B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>15d-<z:chebi fb="0" ids="26346">PGJ</z:chebi>(2)-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> occurs through multiple caspase activation pathways involving caspase-8 and caspase-9, and is prevented by pretreatment with the pan-caspase inhibitor ZVAD (z-Val-Ala-Asp) </plain></SENT>
<SENT sid="4" pm="."><plain>NF-kappa B inhibition is accompanied by rapid down-regulation of NF-kappa B-dependent antiapoptotic gene products, including cellular inhibitor-of-<z:mpath ids='MPATH_3'>apoptosis</z:mpath> protein 1 (cIAP-1), cIAP-2, X-chromosome-linked inhibitor-of-<z:mpath ids='MPATH_3'>apoptosis</z:mpath> protein (XIAP), and FLICE-inhibitory protein (cFLIP) </plain></SENT>
<SENT sid="5" pm="."><plain>These effects were mimicked by the <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> MG-132, but not by the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="9753">troglitazone</z:chebi>, suggesting that 15d-<z:chebi fb="0" ids="26346">PGJ</z:chebi>(2)-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is independent of PPAR-gamma </plain></SENT>
<SENT sid="6" pm="."><plain>Knockdown of the NF-kappa B p65-subunit by lentiviral-mediated shRNA interference also resulted in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction in malignant B cells with constitutively active NF-kappa B </plain></SENT>
<SENT sid="7" pm="."><plain>The results indicate that inhibition of NF-kappa B plays a major role in the proapoptotic activity of 15d-<z:chebi fb="0" ids="26346">PGJ</z:chebi>(2) in aggressive B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> characterized by aberrant regulation of NF-kappa B </plain></SENT>
</text></document>